Back

Novo Nordisk A/S Class B

Ticker: 0QIU ISIN: DK0062498333
Add to portfolio Portfolio analysis in 2min
Stock Large-cap Dividend payer
Market cap
DKK 19.90B
P/E
0.39
Forward P/E
0.00
Profit margin
33.40%
Revenue growth QoQ
31.60%
Div. yield
1.69%
Beta
0.24
DKK 280.85 2.29%
Price as of 2026-09-18 · LSE

Performance by timeframe

Rolling returns
1 Month -6.75%
6 Months +26.22%
1 Year -23.04%
5 Years -0.42% p.a.-2.10%
10 Years +9.12% p.a.+139.24%
Since inception +16.47% p.a.+3,898.66%
Calendar year returns
YTD -10.00%
2025 -45.95%
2024 -9.88%
2023 +50.74%
2022 +29.52%
2021 +73.99%

Key stats

Market cap
19.90B
P/E
0.39
Dividend yield
1.69%
Beta
0.24
52-week range
214.33 - 391.24
50-day MA
1,089.11
200-day MA
994.15
Section 1

Business overview

Company profile data from fundamentals.

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Rare Disease. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, glucagon, needles, and other chronic diseases. The Rare Disease segment offers products in the areas of haemophilia, blood disorders, endocrine disorders, growth disorders, and hormone replacement therapy. The company has a collaboration agreement with Gilead Sciences, Inc.; and research collaboration with Novo Nordisk to discover cell-specific carriers of nucleic acid therapeutics. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Country Denmark
Exchange LSE
Section 2

Financial quality

Profitability and balance-sheet quality indicators from reported fundamentals.

Profitability

ROE 81.54%
ROA 21.76%
Profit margin 33.40%
Operating margin 43.20%
Revenue/share TTM 89.38
Revenue TTM 201.33B
EBITDA 92.89B
Gross profit TTM 148.51B
Beta 0.24

Valuation

Trailing P/E 0.39
Forward P/E 0.00
P/B 0.00
P/S 0.12
EV/EBITDA 0.00
EV/Revenue 0.00
Section 3

Earnings

Earnings metrics from company highlights and earnings datasets.

EPS estimate (current year) 0.00
Quarterly earnings growth 47.30%
Revenue TTM 201.33B
Section 4

Dividends & corporate actions

Dividend and split fields from fundamentals.

Dividend yield 1.69%
Dividend per share 14.1500
Section 5

Ownership / analyst view

Institutional ownership and analyst estimate fields when available.

Ownership & short interest

Short ratio 0.00

Details

Instrument metadata and source update timestamps.

Symbol 0QIU
Name Novo Nordisk A/S Class B
Asset type STOCK
Exchange LSE
Currency DKK
ISIN DK0062498333
Country UK
Code + exchange 0QIU.LSE
Fundamentals updated 2026-08-18

The information provided on this platform is for informational purposes only and should not be considered as financial or investment advice. Insightfolio does not provide investment advice, personalized recommendations, or guidance regarding the purchase, holding, or sale of financial assets. The tools and content are intended for educational purposes only and are not tailored to individual circumstances, financial needs, or objectives.

Insightfolio assumes no liability for the accuracy, completeness, or reliability of the information presented. Users are solely responsible for verifying the information and making independent decisions based on their own research and careful consideration. Use of the platform should not replace consultation with qualified financial professionals.

Investments involve risks. Users should be aware that the value of investments may fluctuate and that past performance is not an indicator of future results. Investment decisions should be based on personal financial goals, risk tolerance, and independent evaluation of relevant information.

Insightfolio does not endorse or guarantee the suitability of any particular financial product, security, or strategy. Any projections, forecasts, or hypothetical scenarios presented on the platform are for illustrative purposes only and are not guarantees of future outcomes.

By accessing the services, information, or content offered by Insightfolio, users acknowledge and agree to these terms of the disclaimer. If you do not agree to these terms, please do not use our platform.

Instrument logos provided by Elbstream.